Futura Medical (GB:FUM) has released an update.
Futura Medical plc has announced the expected U.S. launch of its leading sexual health product, Eroxon®, before the year’s end as reported in Haleon’s HY 2024 results. The company also noted that its trading aligns with current market forecasts for FY2024, which do not account for the upcoming U.S. launch. Further updates on trading and guidance will be provided with the Interim results in September.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.
